Abstract 1501: Exceptional response to anti HER-2 targeted therapy in patient with HER2/neu negative breast cancer with HER2/neu positive CTCs

Background: Treatment resistance is a major challenge in the management of metastatic breast cancer due to several clinical and molecular factors. Tumor heterogeneity is a very important factor responsible for treatment resistance and failures in solid tumors, including breast cancer. In this disease, several studies demonstrated biomarkers conversions when comparing primary disease and distant recurrence supporting a mandatory repeated tissue...